In Vivo and In Silico Assessment of Diabetes Ameliorating Potentiality and Safety Profile of *Gynura procumbens* Leaves

Md. Rafat Tahsin,1 Tanzia Islam Tithi,2 Sabiha Rahman Mim,3 Ehfazul Haque,4 Arifa Sultana,5 Nasiba Binte Bahar,5 Raju Ahmed,4 Jakir Ahmed Chowdhury,2 Abu Asad Chowdhury,4 Shaila Kabir,4 Fahima Aktar,4 Md. Sahab Uddin6,7 and Md. Shah Amran4

1Department of Pharmaceutical Sciences, North South University, Dhaka 1229, Bangladesh
2Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Dhaka, Dhaka 1000, Bangladesh
3Department of Pharmaceutical Science, Uppsala University, Uppsala, Sweden
4Molecular Pharmacology and Herbal Drug Research Laboratory, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Dhaka, Dhaka 1000, Bangladesh
5Department of Pharmacy, Faculty of Pharmacy, University of Dhaka, Dhaka 1000, Bangladesh
6Department of Pharmacy, Southeast University, Dhaka, Bangladesh
7Pharmakon Neuroscience Research Network, Dhaka, Bangladesh

Correspondence should be addressed to Md. Sahab Uddin; msu-neuropharma@hotmail.com and Md. Shah Amran; amranms@du.ac.bd

Received 2 July 2021; Revised 29 November 2021; Accepted 8 December 2021; Published 19 January 2022

Academic Editor: Claudia Di Giacomo

Copyright © 2022 Md. Rafat Tahsin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Background.** Diabetes mellitus is one of the most notable health dilemmas. Analyzing plants for new antidiabetic remedies has become an impressive territory for life science researchers. *Gynura procumbens* has long been used to treat diabetes. Thus, we strived to ascertain the hypoglycemic potentiality of extract of leaves of *G. procumbens* by in vivo and in silico approaches. Methods. Fresh leaves of *G. procumbens* were collected and shade-dried to prepare ethanolic extracts to evaluate pharmacological parameters. Diabetes was induced in rats via injecting alloxan through the intraperitoneal route at a dose of 150 mg/kg body weight. Humalyzer 3000 was used to perform a biochemical assay of collected samples from rats. Anti-hyperglycemic activity study along with overdose toxicity test was performed. The pharmacological activity of this plant was also evaluated through a molecular docking study. This in silico study investigated the binding affinity of natural ligands from *G. procumbens* against glycoside hydrolase enzymes. Results. We detected a peak plasma concentration of *G. procumbens* at 3 hours 45 minutes that is roughly similar to the peak plasma concentration of metformin. Again, in OGTT and anti-hyperglycemic tests, it has been ascertained that both plant extract and metformin can exert significant (P < 0.05) and highly significant (P < 0.01) hypoglycemic activity in a dose-oriented manner. Metformin exhibited better therapeutic efficacy than that of plant extract, but it possessed null statistical significance. Also, our safety profile expressed that, similar to metformin, the plant extract can restore the disturbed pathological state in a dose-oriented approach with a wide safety margin. In silico study also validated the potentialities of natural constituents of *G. procumbens*. Conclusion. This study suggested that *G. procumbens* can be considered as potential antidiabetic plant. Robust and meticulous investigation regarding plant chemistry and pharmacology in the future may bring about a new dimension that will aid in discovering antidiabetic drugs from this plant in the diabetes management system.

1. Introduction

Diabetes mellitus is characterized as one of the major epidemics in South Asia. Over 84 million people aged from 20 to 79 are suffering from type II diabetes that represents one-fifth of the total diabetic population [1, 2]. This number may get remarkably increased by 78% in 2045 [2]. Since the percentage of gross domestic product (GDP) expenditure in the health care sector has remained the same for the past two decades, this chronic disease leads to an enormous burden
Evidence-Based Complementary and Alternative Medicine

2. Materials and Methods

2.1. Drugs, Chemicals, and Instruments. Ethanol and alloxan were bought from Sigma Aldrich, Germany. Standard antidiabetic drug metformin was obtained from Healthcare Pharmaceutical Limited as a gift sample. The blood serum analyzing kits, total cholesterol, HDL, LDL, triglyceride, SGOT, SGPT, and creatinine were bought from Plasmatic Laboratory Product Ltd., UK. Humalyzer 3000 (semi-automated clinical chemistry analyzer originated from Medigroup Asia Limited, Cambodia) was used to assess the biochemical parameters, and the glucometer Alere GI of Alere Inc., USA, was bought from Shahbag, Dhaka, Bangladesh.

2.2. Plant Collection and Extract Preparation. G. procumbens leaves were collected from the medicinal plant garden of the Faculty of Pharmacy of the University of Dhaka. The authentication and taxonomic identification were then carried out. The plant specimen was kept at Bangladesh’s National Herbarium according to their guidelines. The herbarium authorities assigned the accession number 47380, dated 11-2-2019 for future reference.

The leaves were shade-dried for 7–10 days before being coarsely pulverized. The powdered leaves were steeped in 70% ethanol for 96 hours while being vigorously shaken. The extract was filtered when it had finished soaking, and the filtered liquid was collected. The extracted solution was then transferred to a rotary evaporator machine to concentrate it. Finally, the dried extract was carefully collected and stored for future use.

2.3. Experimental Animal Handling. Adult healthy male Wistar rats (125–200 gm) were collected from the Zoology Department of Chittagong University, Chittagong, Bangladesh, and kept at the Institute of Nutrition and Food Science, University of Dhaka, under a 12 hour dark/light cycle at a constant temperature of 25°C. Standard pellet diet and clean water were provided regularly. The rats were kept there for acclimatization before the investigation started. All experimental procedures involving rats were carried out in compliance with the guidelines established by the Institutional Animal Ethics Committee (IEAC). Animals were treated and handled in accordance with the guidelines of the Swiss Academy of Medical Sciences (SAMS) and the Swiss Academy of Sciences (SCNAT).

2.4. Experimental Guidelines. All tests were carried out in accordance with the ethical principles outlined in the Declaration of Helsinki 2013. The entire course of this research was performed in strict adherence with the “3R” principles, a fundamental element of Swiss and international guidelines regulating the exploitation of animals for experimental purposes. The first “R” stands for “replacement” that involves both absolute replacements (replacing animal models with computer-simulated models) and relative replacements (replacing live animals by cell or tissue cultures, or replacing vertebrates with invertebrates). In order to adhere to the concept of “replacement,” our study was initiated with an in silico analysis. However, this model failed to generate adequate data. Hence, an animal model was employed for further investigation. Since investigation for antidiabetic potential necessitates animals with specified pancreas and beta cells, mammalian vertebrates (i.e., rats) were chosen instead of invertebrates. The second “R” stands...
Evidence-Based Complementary and Alternative Medicine

for “reduction,” which refers to any approach that will lead to fewer animals being utilized to achieve sufficient data to solve the research queries or in optimizing the information acquired from each animal. To comply with this guideline, the sample size was estimated using the “power analysis method,” and on the basis of this calculation, ten rats per group were taken for this study. The third “R” denotes “refinement,” which implies lessening the amount of suffering caused to the experimental animals by alleviating their pain. For this purpose, the tail tips of rats were rubbed with isopropyl alcohol before and after each measurement of blood glucose levels to make the procedure more tolerable and lessen the pain caused by pinching. The rats were well-fed throughout this entire research, and at the end of this study, they were euthanized in a painless manner under the influence of general anesthesia according to the 2013 edition of Guidelines for the Euthanasia of Animals.

2.5. Sample Size Estimation for the Animal Model. The sample size of our animal model study was determined applying the “power analysis method.” Calculations were performed manually using the following formula:

\[
\text{sample size} = \frac{2 \times \text{SD}^2 ((Z_{\alpha/2} + Z_{\beta})^2) \times d^2}{d^2}
\]

where \(\text{SD} =\) standard deviation from pilot study, \(Z_{\alpha/2} = Z_{0.05/2} = 1.96\) (according to \(Z\) table) with 5% type I error rate, \(Z_{\beta} = Z_{0.20} = 0.842\) (according to \(Z\) table) at 80% power. \(d = \) difference between two (pretreatment and posttreatment) mean values of blood glucose levels = effect size.

The theoretical sample size was adjusted for the expected attrition of the rats. From our prior experience, it was observed that alloxan treatment might result in the death of 10% of rats. So the actual sample size was estimated by dividing the theoretical sample size by 0.9.

In our pilot study, ten rats were employed as “alloxan control,” and on the basis of the preceding calculation, each of our preclinical trials included ten rats. Following intraperitoneal administration of alloxan at a dose of 150 mg/kg body weight, the rats were left untreated for about four weeks. This resulted in a substantial increase in their blood glucose levels. After four weeks, the mean blood glucose level of rats was found to be 24.74 mmol/L, with a standard deviation (SD) of 5.12.

According to our prior experiment, it can be interpreted that if the mean value of blood glucose is found to be 18.05 mmol/L following treatment with the plant extract, it can be inferred that the extract can significantly lower the rise in blood glucose level \((p < 0.05)\).

So, \(d = \) difference between two mean values = 24.74 – 18.05 = 6.85.

Hence, theoretical sample size = \(2 \times 24.74^2 / (1.96 + 0.842)^2 / 6.85^2 = 8.77\).

Then we adjusted this theoretical sample size for expected attrition to obtain the actual sample size.

So actual sample size = \(8.77 / 0.9 = 9.74\).

Therefore, ten rats per group were taken for the study.

2.6. Dose Selection. A pilot analysis was performed prior to the commencement of the study. From this pilot investigation, it was noted that the plant extract \((G. procumbens)\) began exerting its pharmacological effect at a dose of 500 mg/kg, denoting its MEC (minimum effective concentration) value at a greater dose than 500 mg/kg. As the dose was increased, a constant rise in this effect was observed. Eventually, when the dose was raised from 1,000 mg/kg to 1,200 mg/kg, no noticeable effect on the pharmacological action was detected. This indicated that the receptors related to the pharmacological action of the plant began saturated at a dose of 1,000 mg/kg. The doses of Metformin (standard drug) were chosen in the same way.

2.7. Biological Sample Collection. Blood samples were collected via puncturing the tip of the tail of rats for the assessment of blood glucose levels. On the contrary, blood was collected by puncturing the heart immediately after sacrifice and taken to a microcentrifuge tube. The collected samples were centrifuged at 5,000 rpm for 5 minutes to obtain the supernatant fluid. This fluid was then transferred to another microcentrifuge tube to conduct biochemical assays.

The kidney and liver were immediately separated from the animal body after sacrifice and washed thoroughly by ice-cold saline in order to conduct kidney and liver function tests.

2.8. Experimental Design. The body weight of individual rats was weighed, and animals were divided into different groups to check peak plasma concentration (Table 1), oral glucose tolerance test (Table 2), anti-hyperglycemic activity analysis (Table 3), and overdose toxicity analysis (Table 4) where an even distribution of rodents as per their body weight has been taken place, and each group contained ten rats.

In Table 3, the alloxan control group represents rats that were treated with alloxan only. N/A refers that no therapeutic treatment was administered to rats belonging to this group.

2.9. Evaluation of Antidiabetic Properties. Alloxan was applied to induce diabetes in the rat model. Alloxan was first dissolved in a cold citrate buffer \((0.1 \text{ M; pH} = 4.5)\). Then the rats were treated with this alloxan at a dose of 150 mg/kg body weight through their intraperitoneal routes. After alloxan administration, they were monitored for...
hyperglycemia by measuring blood glucose levels four times a day at a six-hour interval, and within 72 hours post alloxan therapy, it was found that all alloxan-treated rats had an average blood glucose level greater than 15 mmol/L that clearly indicated their hyperglycemic or diabetic conditions. Metformin and extract of *G. procumbens* treatments were administered to rats via the oral route.

2.10. Enzymatic Activity Assay. The activities of hexokinase, aldolase, phosphoglucoisomerase, fructose-1, 6-diphosphatase, and glucose-6-phosphatase were analyzed from the liver and kidney [30–32]. Particularly, enzymes that catalyze irreversible reactions in gluconeogenesis are mostly available in the proximal tubular region in the kidney [31, 33] along with the perportal region of liver acinus [34–36], whereas enzymes associated with glucose degradation are mostly available in the distal regions of the nephron [37–39] as well as centrilobular hepatocytes [35, 40–43].

2.11. Estimation of Biochemical Parameters. Blood glucose level was assessed using a glucometer. Besides making use of Humaluzer 3000, lipid profile, kidney, and liver functioning tests were performed. Furthermore, the activities of gluconeogenic and glycolytic enzymes were analyzed from the kidney and liver samples.

Table 1: Test for peak plasma concentration levels.

| Group number | Group status | Treatment specimen | Dose of treatment specimen (mg/kg) | Group abbreviation |
|--------------|--------------|--------------------|------------------------------------|-------------------|
| 1            | Alloxan + *G. procumbens* | *G. procumbens* | 150 mg/kg + 2,000 mg/kg | g + G<sub>2000</sub> |

Table 2: Oral glucose tolerance test (OGTT).

| Group number | Group status | Treatment specimen | Dose of treatment specimen (mg/kg) | Group abbreviation |
|--------------|--------------|--------------------|------------------------------------|-------------------|
| 1            | Control      | Physiological saline | 10 mL/kg                  | C                |
| 2            | Glucose control | Glucose           | 10 gm/kg                    | g                |
| 3            | Glucose + metformin | Metformin      | 10 gm/kg + 100 mg/kg        | g + M<sub>100</sub> |
| 4            | Glucose + metformin | Metformin      | 10 gm/kg + 200 mg/kg        | g + M<sub>200</sub> |
| 5            | Glucose + metformin | Metformin      | 10 gm/kg + 500 mg/kg        | g + M<sub>500</sub> |
| 6            | Glucose + *G. procumbens* | *G. procumbens* | 10 gm/kg + 500 mg/kg        | g + G<sub>500</sub> |
| 7            | Glucose + *G. procumbens* | *G. procumbens* | 10 gm/kg + 750 mg/kg        | g + G<sub>750</sub> |
| 8            | Glucose + *G. procumbens* | *G. procumbens* | 10 gm/kg + 1,000 mg/kg      | g + G<sub>1000</sub> |

Table 3: Anti-hyperglycemic activity analysis.

| Group number | Group status | Treatment specimen | Dose of treatment specimen (mg/kg) | Group abbreviation |
|--------------|--------------|--------------------|------------------------------------|-------------------|
| 1            | Control      | Physiological saline | 10 mL/kg                  | C                |
| 2            | Alloxan control | Alloxan           | 150 mg/kg                    | A                |
| 3            | Alloxan + metformin | Alloxan + metformin | 150 mg/kg + 100 mg/kg + 60 mg/kg | A + M<sub>100</sub> |
| 4            | Alloxan + metformin | Alloxan + metformin | 150 mg/kg + 200 mg/kg + 60 mg/kg | A + M<sub>200</sub> |
| 5            | Alloxan + metformin | Alloxan + metformin | 150 mg/kg + 500 mg/kg + 60 mg/kg | A + M<sub>500</sub> |
| 6            | Alloxan + *G. procumbens* | Alloxan + *G. procumbens* | 150 mg/kg + 500 mg/kg | A + G<sub>500</sub> |
| 7            | Alloxan + *G. procumbens* | Alloxan + *G. procumbens* | 150 mg/kg + 750 mg/kg | A + G<sub>750</sub> |
| 8            | Alloxan + *G. procumbens* | Alloxan + *G. procumbens* | 150 mg/kg + 1,000 mg/kg      | A + G<sub>1000</sub> |
| 9            | Metformin    | Metformin         | 100 mg/60 kg                 | M<sub>100</sub>  |
| 10           | Metformin    | Metformin         | 200 mg/60 kg                 | M<sub>200</sub>  |
| 11           | Metformin    | Metformin         | 500 mg/60 kg                 | M<sub>500</sub>  |
| 12           | *G. procumbens* | *G. procumbens* | 500 mg/kg                    | G<sub>500</sub>  |
| 13           | *G. procumbens* | *G. procumbens* | 750 mg/kg                    | G<sub>750</sub>  |
| 14           | *G. procumbens* | *G. procumbens* | 1,000 mg/kg                  | G<sub>1000</sub> |

Table 4: Overdose toxicity analysis.

| Group number | Group status | Treatment specimen | Dose of the treatment specimen (gm/kg) | Group abbreviation |
|--------------|--------------|--------------------|--------------------------------------|-------------------|
| 1            | Control      | Physiological saline | 10 mL/kg                  | C                |
| 2            | Alloxan + metformin | Alloxan + metformin | 150 mg/kg + 5 gm/60 kg *         | A + M             |
| 3            | Alloxan + *G. procumbens* | Alloxan + *G. procumbens* | 150 mg/kg + 25 gm/60 kg *        | A + G             |
| 4            | Metformin    | Metformin         | 5 gm/60 kg *                    | M                 |
| 5            | *G. procumbens* | *G. procumbens* | 25 gm/60 kg *                   | G                 |

* 50 times of lower dose = overdose
2.12. Overdose Toxicity Determination. To determine the toxicity of an overdose, 50 rats were separated into five groups. An overdose is defined as a dose containing 50 times the medium dose.

The actual purpose of the overdose toxicity study was to determine the minimum dose of any of the treatments (either metformin or G. procumbens) that would be lethal for 100% of rats. For this study, we took 50 rats and split them into five classes to study the effects of overdosing. Rats in groups 2 and 4 were treated with metformin, whereas rats in groups 3 and 5 were treated with G. procumbens in increasing dose levels (about 5 times, 10 times, 20 times, 30 times, 40 times, and finally 50 times) of the medium dose. The rats were kept under continuous observation until 100% lethality was noticed in any of the treatment groups (either metformin-treated or G. procumbens–treated groups). At a dose 50 times higher than the medium dose, all metformin-treated rats (groups 2 and 4) were found dead, whereas G. procumbens–treated rats (groups 3 and 5) remained alive. Hence, we considered this dose (50 times the medium dose) as an overdose. Our toxicity trial was terminated at this point as 100% lethality was attained in one of the treatment groups (i.e., metformin-treated groups).

2.13. Docking Studies of Gynura procumbens Phytochemicals to Characterize Different Pharmacological Activities. After an extensive literature study, it was found that the G. procumbens extract produced an antidiabetic effect through the inhibition of alpha-amylase and alpha-glucosidase enzymes. In order to perform in silico molecular docking study against these two endogenous peptides, a list of 90 compounds of different chemical classes was prepared through a meticulous literature review. The 3D structures of these compounds were downloaded from PubChem and later optimized through PyRx. Crystal structure of alpha-amylase (3BAI) and N-terminal alpha-glucosidase (maltase-glucoamylase) (2QMI) were downloaded from the RCSB-PDB. This server was also used to determine the binding site of the standard acarbose, which was later specified in the docking process. These macromolecules were prepared for docking study using PyMol. Next, molecular docking was performed using Autodock Vina, and the results were sorted using Microsoft Excel. Moreover, an interaction study was conducted using the Biovia Discovery Studio Visualizer.

2.14. Statistical Analysis. All study parameters belonging to each group displayed as mean ± SD. The “one-way ANOVA test” was conducted to interpret intergroup heterogeneity in terms of diverse biological parameters to determine the statistical significance. “SPSS 16” software was used for the analysis. The result was considered statistically significant when “p” value was obtained less than 0.05 (p < 0.05) and highly significant when the “p” value was found less than 0.01 (p < 0.01).

3. Results

3.1. Determination of Peak Plasma Concentration. In this study, ten alloxan-induced rats were given a 2 g/kg dose of G. procumbens as shown in Table 1. After that, blood glucose levels were tested every 45 minutes. Figure 1 shows that blood glucose levels are dropping before they reached 225 minutes, or 3 hours and 45 minutes. As a result, the peak plasma concentration may exist between 3 and 4 hours, and the peak plasma time was obtained at 3 hours 45 minutes when the concentration could be found maximum.

3.2. Impact on Body Weight during Treatment. In our experiment, alloxan significantly reduced the body weight of experimental rodents. In the treatment groups, plant extract successfully elevated the body weight of alloxan-induced diabetic rats, but metformin played a role in further reducing the body weight as shown in Figure 2.

3.3. Oral Glucose Tolerance Test. We divided 80 rats into 8 classes for the oral glucose tolerance test. For OGGT, the rats were kept on an overnight fast prior to glucose administration. Except for the rats in group 1, all of the rats were induced with 10 g/kg glucose, and the blood glucose levels were tested after 30 minutes, and then all of the rats in groups 3–8 were induced with the respective treatment. In this test, blood glucose levels for all rats were checked for each 30 minutes interval for 3.5 hours. Figure 3 shows that the extract can significantly reduce the elevated blood glucose level of nondiabetic glucose-induced rats.

3.4. Change in Blood Glucose Level. We took 140 rats and divided them into 14 classes to see how the extract affected blood glucose levels. Initially, blood glucose levels were determined, and alloxan was injected into rats in groups 2–8. Within 3 days, diabetes had been induced. We kept them untreated for 14 days. Then, on day 14, the treatment began. Rats in groups 3–8 were given their respective medications and doses until day 42. As a result, rats in groups 9–14 were also given their medications, but these groups were not treated with alloxan. From days 14 to 42, they were given medication. In addition, rats in group 1 were given standard food and water.

Alloxan is one of the most available compounds for inducing diabetes in experimental rodents. According to our study, the blood glucose levels of group 1 rats were detected to be normal that is shown in Figure 4. However, in the diabetic controlled group, due to destruction of beta cells and untreated condition, the blood glucose level was higher than all other groups. In all the metformin and extract-treated groups, the elevated blood glucose levels were decreased in the same pattern but not to the same extent. Nevertheless, the reduction of blood glucose in the metformin-treated group was a little bit higher than that of the extract-treated group, but it does not possess any statistical significance.

3.5. Kidney Function Test. In our study, creatinine level was obtained to be lower in the treatment groups in contrast with the alloxan control group as shown in Figure 5. The highest level of creatinine was observed in the alloxan control group due to its destructive effects. No significant difference in
A creatinine deduction was found between metformin and extract-induced treatment groups.

### 3.6 Liver Function Test

In the liver functioning test, the SGOT and SGPT levels were enhanced significantly in alloxan-induced diabetic rats. The SGOT and SGPT levels of treatment groups were lower than all the other groups, including the alloxan control group. In the treatment groups containing the extract, the protective effect of *G. procumbens* extract declined the liver enzymes. It reduced the abnormally increased level of SGOT and SGPT levels as shown in Figures 6 and 7.

### 3.7 Lipid Profile Function Test

Total cholesterol, LDL, and triglyceride levels of treatment groups were lower than alloxan-controlled groups as alloxan also increased the level of
cholesterol, LDL, and triglyceride level as shown in Figures 8, 9, and 10, respectively. HDL level was also found to be highest in the negative control group and the lowest in the alloxan control group as shown in Figure 11. As a consequence, the level of HDL was increasing with the enhancement of dose both in the case of metformin and plant extract.

3.8. Glycolytic and Gluconeogenic Enzyme Activity Test. The activities of glycolytic enzymes were found abnormal in diabetic rats. In contrast, the treatment groups reflected the effectivity of plant extract and metformin by reversing that condition to a normal level as presented in Table 5 and 6. The hexokinase and phosphoglucoisomerase activities were seen to be decreased, and aldolase activity was seen to be increased in the alloxan control group compared to the treatment groups. G. procumbens extract significantly normalized the activities of glycolytic enzyme in a dose-dependent manner. A similar effect was obtained in the case of T. arjuna extract [44].

3.9. Overdose Toxicity Study. Rats from both the normal and the alloxan-induced metformin-treated groups died in this experiment. All of the rats in the alloxan-treated group died within 3 hours, while the average rats in the metformin-treated group died within 4 hours. However, both classes of rats treated with alloxan + G. procumbens and G. procumbens remained alive.

In an overdose toxicity study, it has been observed that even 50 times greater than that of the medium dose (750 mg/kg) of G. procumbens did not cause lethality in rodents, indicating the broad safety profile of G. procumbens. On the contrary, all metformin-treated rats (i.e., 100% rats) died within three hours of receiving a 50-fold higher dose of the drug as illustrated in Figure 12.

3.10. Docking Studies. The results of the docking study against 3BAJ and 2QMJ are presented in Table 9 and 10, respectively. It is found that a total of 22 compounds displayed better binding as compared to the standard acarbose in the case of alpha-amylase. Twenty compounds also found stronger binding affinity compared to acarbose in the case of the N terminal maltase-glucoamylase. In both docking
studies, flavonoids compounds showed higher binding affinity and similar interaction compared with reference drug, acarbose, as shown in Figures 13 and 14.

4. Discussion

Alloxan-induced diabetic groups had lower body weight than normal, and plant extract was observed to reverse this condition in a dose-dependent manner [45]. Apart from that, it was obtained that the extract of *G. procumbens* can effectively reduce the elevated blood glucose level gradually in alloxan-induced diabetic rats. Prior studies also supported this data [19]. Alloxan devastatingly increased the creatinine level in rats whereas *G. procumbens* reversed the condition [46, 47].

In the case of blood glucose-lowering effect, SGOT, SGPT, creatinine, total cholesterol, LDL, triglyceride, and HDL levels of all the drug-treated and extract-treated groups showed better conditions than the diabetic control group but worsened the condition than the healthy control group and among the drug and extract-treated groups, the drug-treated groups showed a little bit better results in all these parameters; still, no statistical significance (*P* > 0.05) was found when a comparison was drawn between these two. The condition was found to improve with the enhancement of the dose. The treatment of *G. procumbens* extract reversed the abnormal level of lipid profile towards the normal state in previous studies [48, 49]. Additionally, we observed that the SGOT, SGPT, creatinine, total cholesterol, HDL, triglyceride, and blood glucose levels of normal healthy rat treated with *G. procumbens* and metformin was almost similar to the control group that can be termed as a marker of safety.

Furthermore, it can also be said that further modification and isolation of the therapeutic compound of *G. procumbens* may provide us a better effect than metformin, as there is no statistical significance in the difference of the test results between groups 3 and 4. But metformin itself is a single API that was given in doses 100, 250, and 500 mg/kg body weight; on the other hand, the plant extract was given at a dose of 500, 750 and 1,000 mg/kg body weight that contains numerous compounds, and hence, naturally, its antidiabetic effects will be lower than that of metformin.

*G. procumbens* contains significant amounts of bioactive constituents, including flavonoids, phenolic compounds, steroids, alkaloids, terpenoids, and glycosides [50]. Several literature reviews and scientific findings highlighted the importance of flavonoids and phenolic compounds to inhibit the elevation of blood glucose levels. These natural compounds affect plasma glucose levels by inhibiting
Figure 5: Creatinine level of rats belonging to 14 groups throughout receiving respective treatments. Values were expressed as mean ± SD (n = 10/group). * p < 0.05 and ** p < 0.01 indicate significant difference from the disease group (C = control group, A = alloxan-treated group, M = metformin, A + M = alloxan + metformin, A + G = alloxan + Gynura, and G = G. procumbens).

Figure 6: SGOT level of rats belonging to 14 groups throughout receiving respective treatments. Values were expressed as mean ± SD (n = 10/group). * p < 0.05 and ** p < 0.01 indicate significant difference from the disease group (C = control, A = alloxan, M = metformin, A + M = alloxan + metformin, A + G = alloxan + Gynura, and G = G. procumbens).
Figure 7: SGPT level of rats belonged to 14 groups throughout receiving respective treatments. Values were expressed as mean ± SD (n = 10/group). *p < 0.05 and **p < 0.01 indicate significant difference from the disease group (C = control group, A = alloxan-treated group, M = metformin, A + M = alloxan + metformin, A + G = alloxan + Gynura, and G = G. procumbens).

Figure 8: Total cholesterol level of rats belonging to 14 groups throughout receiving respective treatments. Values were expressed as mean ± SD (n = 10/group). *p < 0.05 and **p < 0.01 indicate significant difference from the disease group (C = control group, g = glucose-treated group, M = metformin, A + M = alloxan + metformin, A + G = alloxan + Gynura, and G = G. procumbens).
Figure 9: LDL level of rats belonging to 14 groups throughout receiving respective treatments. Values were expressed as mean ± SD (n = 10/group). * p < 0.05 and ** p < 0.01 indicate significant difference from the disease group (C = control group, A = alloxan-treated group, M = metformin, A + M = alloxan + metformin, A + G = alloxan + Gynura, and G = G. procumbens).

Figure 10: Triglyceride level of rats belonging to 14 groups throughout receiving respective treatments. Values were expressed as mean ± SD (n = 10/group). * p < 0.05 and ** p < 0.01 express significant difference (p < 0.05) and high significant difference (p < 0.01) from the disease group, respectively (C = control group, A = alloxan-treated group, M = metformin, A + M = alloxan + metformin, A + G = alloxan + Gynura, and G = G. procumbens).
alpha-amylase and alpha-glucosidase enzymatic activity, hence giving hypoglycemic efficacy. Rutin, nicotiflorin, myricitin, and eriocitrin of flavonoid group and 3,4 dicaffeoylquinic acid, 4,5 dicaffeoylquinic acid, chlorogenic acid, feruloylquinic acid, and glucoronide from the phenolic group are key compounds and show better binding affinity than acarbose. Thus, these natural compounds refrain from carbohydrate breakdown into glucose in the small intestine and give synergistic effects on acarbose, a glucose-lowering drug.

According to the findings of our study, it was observed that reduction in food intake had no effect on the blood glucose levels of rats. However, when the

Response observed from different groups

**Figure 11:** HDL level of rats belonging to 14 groups throughout receiving respective treatments. Values were expressed as mean ± SD (n = 10/group). * p < 0.05 and ** p < 0.01 indicate significant difference from the disease group (C = control group, A = alloxan-treated group, M = metformin, A + M = alloxan + metformin, A + G = alloxan + Gynura, and G = G. procumbens).

**Table 5:** Effect of G. procumbens on the activities of glycolytic enzymes in the liver of control and experimental rats.

| Group     | Hexokinase (n moles of glucose-6-phosphate formed/min/mg/protein) | Aldolase (n moles of glyceraldehyde formed/min/mg protein) | Phosphoglucoisomerase (n moles of fructose formed/min/mg protein) |
|-----------|-------------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------------|
| C         | 397.26 ± 7.39                                                     | 156.3 ± 7.13                                               | 49.32 ± 5.49                                                     |
| A         | 103.36 ± 5.86                                                     | 244.82 ± 30.7                                             | 27.32 ± 4.55                                                     |
| A + M100  | 228.62 ± 15.97*                                                   | 201.9 ± 11.56*                                            | 33.28 ± 4.95*                                                   |
| A + M200  | 333.8 ± 11.20*                                                   | 176.14 ± 8.75*                                            | 41.24 ± 1.63*                                                   |
| A + M500  | 401.4 ± 10.05*                                                   | 155.86 ± 14.2*                                            | 49.28 ± 3.40*                                                   |
| A + G500  | 213.86 ± 12.20*                                                  | 210.86 ± 9.94*                                            | 30.4 ± 4.21*                                                   |
| A + G750  | 325.9 ± 11.05*                                                   | 192.12 ± 11.25*                                           | 38.64 ± 1.50*                                                   |
| A + G1000 | 378.56 ± 21.88*                                                  | 157.64 ± 8.20*                                            | 47.38 ± 2.30*                                                   |
| M100      | 391.24 ± 8.56                                                    | 161.74 ± 6.95                                             | 46.74 ± 6.56                                                    |
| M200      | 393.16 ± 8.91                                                    | 152.58 ± 7.07                                             | 50.04 ± 4.43                                                    |
| M500      | 395.64 ± 6.87                                                    | 151.68 ± 6.34                                             | 47.7 ± 3.08                                                     |
| G500      | 396.44 ± 8.34                                                    | 161.92 ± 5.79                                             | 48.76 ± 3.98                                                    |
| G750      | 388.14 ± 2.53                                                    | 159.62 ± 11.89                                            | 49.06 ± 4.04                                                    |
| G1000     | 397.68 ± 7.185                                                   | 150.08 ± 2.85                                             | 50.78 ± 3.64                                                    |

*p < 0.05 indicates a significant difference from the disease group (C = control group, A = alloxan-treated group, M = metformin, A + M = alloxan + metformin, A + G = alloxan + Gynura, and G = G. procumbens).
Table 6: Effect of *G. procumbens* on the activities of glycolytic enzymes in the kidney of control and experimental rats.

| Group | Hexokinase (n moles of glucose-6-phosphate formed/min/mg/protein) | Aldolase (n moles of glyceraldehyde formed/min/mg protein) | Phosphoglucomoisomerase (n moles of fructose formed/min/mg protein) |
|-------|---------------------------------------------------------------|--------------------------------------------------------|---------------------------------------------------------------|
| C     | 291.64 ± 10.52                                               | 222.7 ± 13.64                                         | 31.64 ± 3.67                                                 |
| A     | 82.7 ± 5.05                                                 | 286.26 ± 19.86                                         | 18.48 ± 2.90                                                 |
| A + M100 | 152.46 ± 6.88*                                             | 263.86 ± 11.38*                                         | 24.36 ± 2.31*                                                |
| A + M200 | 234.1 ± 7.3*                                               | 243.06 ± 10.98*                                         | 27.02 ± 2.99*                                                |
| A + M500 | 274.94 ± 9.61*                                             | 229.54 ± 4.75*                                         | 30.3 ± 1.77*                                                 |
| A + G100 | 142.32 ± 10.59*                                            | 267.5 ± 6.04*                                          | 24.98 ± 2.08*                                                |
| A + G50 | 221.92 ± 7.69*                                              | 241.94 ± 10.34*                                         | 30.16 ± 2.26*                                                |
| A + G1000 | 260.28 ± 8.788*                                           | 224.68 ± 7.75*                                         | 28.68 ± 2.07*                                                |
| M100  | 292.56 ± 17.18                                              | 225.74 ± 9.55                                          | 28.4 ± 3.09                                                  |
| M200  | 290.56 ± 8.18                                               | 212.58 ± 2.27                                          | 29.62 ± 2.83                                                 |
| M500  | 288.36 ± 9.30                                               | 225.38 ± 7.98                                          | 30.7 ± 1.93                                                  |
| G500  | 291.16 ± 6.76                                               | 219.34 ± 7.28                                          | 29.98 ± 1.23                                                 |
| G750  | 288 ± 13.13                                                 | 223.74 ± 8.75                                          | 32 ± 1.86                                                    |
| G1000 | 279.6 ± 12.72                                               | 219.42 ± 8.52                                          | 32.8 ± 2.07                                                  |

*p < 0.05 indicates a significant difference from the disease group (C = control group, A = alloxan-treated group, M = metformin, A + M = alloxan + metformin, A + G = alloxan + *Gynura*, and G = *G. procumbens*).

Table 7: Activities of gluconeogenic enzymes in the liver of control and experimental rats.

| Group | Glucose-6-phosphatase (n moles of Pi liberated/min/mg protein) | Fructose-1,6-diphosphatase (n moles of Pi liberated/min/mg protein) |
|-------|---------------------------------------------------------------|---------------------------------------------------------------|
| C     | 44.968 ± 4.26                                                | 33.84 ± 3.51                                                 |
| A     | 101.94 ± 6.79                                                | 347.45 ± 11.54                                              |
| A + M100 | 79.73 ± 3.27*                                              | 62.96 ± 8.18*                                                |
| A + M200 | 61.98 ± 3.06*                                              | 44.18 ± 2.24*                                                |
| A + M500 | 49.76 ± 3.46*                                              | 35.04 ± 1.72*                                                |
| A + G100 | 74.74 ± 8.89*                                              | 70.04 ± 7.69*                                                |
| A + G50 | 56.44 ± 3.78*                                               | 50.936 ± 5.54*                                               |
| A + G1000 | 46.12 ± 3.072*                                             | 40.146 ± 2.40*                                               |
| M100  | 47.052 ± 3.51                                                | 32.458 ± 3.45                                                |
| M200  | 42.516 ± 2.26                                                | 30.62 ± 3.12                                                |
| M500  | 48.56 ± 2.35                                                 | 30.9 ± 0.91                                                 |
| G500  | 45.84 ± 2.32                                                 | 33.52 ± 1.85                                                |
| G750  | 44.652 ± 3.28                                                | 31.64 ± 4.05                                                |
| G1000 | 50.22 ± 3.39                                                 | 31.58 ± 2.03                                                |

*p < 0.05 indicates a significant difference from the disease group (C = control group, A = alloxan-treated group, M = metformin, A + M = alloxan + metformin, A + G = alloxan + *Gynura*, and G = *G. procumbens*).

Table 8: Activities of gluconeogenic enzymes in the kidney of control and experimental rats.

| Group | Glucose-6-phosphatase (n moles of Pi liberated/min/mg protein) | Fructose-1,6-diphosphatase (n moles of Pi liberated/min/mg protein) |
|-------|---------------------------------------------------------------|---------------------------------------------------------------|
| C     | 50.74 ± 4.03                                                 | 22.1 ± 2.98                                                  |
| A     | 129.18 ± 5.10                                                | 219.88 ± 5.13                                                |
| A + M100 | 70.2 ± 7.45*                                               | 40.32 ± 4.39*                                                |
| A + M200 | 59.8 ± 5.16*                                               | 33.62 ± 4.29*                                                |
| A + M500 | 48.12 ± 1.71*                                              | 26.02 ± 1.60*                                                |
| A + G50 | 74.08 ± 9.51*                                               | 45.16 ± 5.74*                                                |
| A + G750 | 62.12 ± 6.09*                                              | 38.94 ± 3.38*                                                |
| A + G1000 | 49.14 ± 2.58*                                             | 34.24 ± 4.46*                                                |
| M100  | 52.18 ± 4.56                                                | 22.1 ± 2.99                                                |
| M200  | 50.16 ± 2.9                                                 | 20.64 ± 2.38                                                |
| M500  | 49.38 ± 1.94                                                 | 24.38 ± 2.22                                                |
| G500  | 50.94 ± 3.40                                                 | 21.04 ± 3.49                                                |
| G750  | 51.04 ± 3.80                                                 | 19.54 ± 1.84                                                |
| G1000 | 51.34 ± 3.09                                                 | 21.54 ± 2.45                                                |

*p < 0.05 indicates a significant difference from the disease group (C = control group, A = alloxan-treated group, M = metformin, A + M = alloxan + metformin, A + G = alloxan + *Gynura*, and G = *G. procumbens*).
Figure 12: Blood sugar level of rats belonging to 1 to 5 groups throughout receiving respective treatments (C = control group, M = metformin, A + M = alloxan + metformin, A + G = alloxan + Gynura, and G = G. procumbens).

Table 9: Binding affinity of natural ligands of G. procumbens with the crystal target alpha-amylase.

| Compound name                      | Binding affinity | Class of compounds |
|------------------------------------|------------------|--------------------|
| Daucosterol                        | −10.5            | Steroid            |
| Glucopyranosyl stigmasterol        | −9.9             | Steroid            |
| 1,5-Dicaffeoylquinic acid          | −9.6             | Phenol             |
| 3,5-Dicaffeoylquinic acid          | −9.6             | Phenol             |
| Luteolin                           | −9.5             | Flavonoid          |
| Beta-stigmasterol                  | −9.5             | Steroid            |
| 3,4-Dicaffeoylquinic acid          | −9.4             | Phenol             |
| Eriocitrin                         | −9.4             | Flavonoid          |
| Apigenin                           | −9.3             | Flavonoid          |
| Rutin                              | −9.3             | Flavonoid          |
| Quercetin                          | −9.2             | Flavonoid          |
| Homoorientin                       | −9.1             | Flavonoid          |
| Nicotiflorin                       | −9.1             | Flavonoid          |
| 5α-Stigmastan-3-one                | −9.1             | Steroid            |
| 4,5-Dicaffeoylquinic acid          | −9.1             | Phenol             |
| Myricetin                          | −9               | Flavonoid          |
| 1,4-Dicaffeoylquinic acid          | −8.9             | Phenol             |
| Kaempferol                         | −8.8             | Flavonoid          |
| Glucuronide                        | −8.8             | Phenol             |
| Negletein                          | −8.7             | Flavonoid          |
| Senecivernine                      | −8.6             | Alkaloid           |
| Seneciphylline                     | −8.5             | Alkaloid           |
| Astragalin                         | −8.4             | Flavonoid          |
| Senkirkine                         | −8.3             | Alkaloid           |
| Senecionine-N-oxide                | −8.3             | Alkaloid           |
| Erucifoline-N-oxide                | −8.1             | Alkaloid           |
| Retrorsine                          | −8.1             | Alkaloid           |
| Neochlorogenic acid                | −8               | Phenolic           |
| Seneciphylline-N-oxide             | −8               | Alkaloid           |
| Chlorogenic acid                   | −7.9             | Phenol             |
| Feruloylquinic acid                | −7.7             | Phenol             |
| Acarbose                           | −7.6             | Reference          |
rats (both nondiabetic and diabetic) were treated with test extract (*G. procumbens*), their body weights accelerated just like the rats belonging to other groups. So it can be inferred that the mechanism of antidiabetic activity of *G. procumbens* may not be attributed to appetite reduction in rats.

Our study also demonstrated a significant elevation in serum insulin level of rats in groups 6, 7, and 8; whereas no significant change was detected in the insulin level of rats belonging to other groups. Therefore, it can be interpreted that the test extract (*G. procumbens*) may boost insulin secretion by affecting pancreatic beta cells. Furthermore, a

---

**Table 10: Binding affinity of natural ligands of *G. procumbens* with the crystal target of N-glucosidase.**

| Compound name                | Binding affinity | Class of compound |
|------------------------------|------------------|-------------------|
| Nicotiflorin                 | −9.3             | Flavonoid         |
| Rutin                        | −9.2             | Flavonoid         |
| Beta-stigmasterol            | −9.1             | Steroid           |
| 5α-Stigmastan-3-one          | −8.8             | Steroid           |
| 3,4-Dicaffeoylquinic acid    | −8.7             | Phenol            |
| 4,5-Dicaffeoylquinic acid    | −8.7             | Phenol            |
| Eriocitrin                   | −8.7             | Flavonoid         |
| Glucopyranosyl stigmasterol  | −8.5             | Steroid           |
| 1,5-Dicaffeoylquinic acid    | −8.5             | Phenol            |
| 1,4-Dicaffeoylquinic acid    | −8.3             | Phenol            |
| 3,5-Dicaffeoylquinic acid    | −8             | Phenol            |
| Astragalin                   | −7.7             | Flavonoid         |
| Luteolin                     | −7.6             | Flavonoid         |
| Myricetin                    | −7.6             | Flavonoid         |
| Feruloylquinic acid          | −7.5             | Phenol            |
| Chlorogenic acid             | −7.5             | Phenol            |
| Negeletin                    | −7.5             | Flavonoid         |
| Quercetin                    | −7.5             | Flavonoid         |
| Apigenin                     | −7.5             | Flavonoid         |
| Neochlorogenic acid          | −7.5             | Phenol            |
| Glucuronide                  | −7.5             | Phenol            |
| Homoorientin                 | −7.4             | Flavonoid         |
| Kaempferol                   | −7.4             | Flavonoid         |
| Caffeoylglucaric acid        | −7.3             | Phenol            |
| Hydroxytyrosol glucoside     | −7.2             | Phenol            |
| Daucosterol                  | −7.2             | Steroid           |
| Senecionine-N-oxide          | −7.1             | Alkaloids         |
| Senkirkine                   | −7               | Alkaloids         |
| Seneciphylline-N-oxide       | −6.9             | Alkaloids         |
| Acarbose                     | −6.7             | Reference         |

---

**Figure 13: Active site interaction between alpha-amylase complex with the flavonoid and reference compound.**

Active interaction site of alpha-amylase (3BAJ) with Luteolin  
Active interaction site of alpha-amylase (3BAJ) with Acarbose
significant rise was observed in the hepatic glycogen content of rats from groups 6, 7, and 8, indicating a possible phenomenon of higher insulin levels. Therefore, it can be deduced that the proposed mechanism through which *G. procumbens* mediates its antidiabetic effects is the increase in the release of insulin.

In addition, our investigation indicated that *G. procumbens* can decline the diabetogenic alloxan-induced concentration of free radicals. The anti-oxidant constituents of *G. procumbens* may serve as free-radical scavenging agents, imparting their actions against hydroxyl radical (•OH), oxygen radical (O$_2$•$^-$) as well as lipid peroxidation. This action may also diminish the rate of tissue damage caused by alloxan-induced free radicals.

After a thorough assessment of alpha-glucosidase and natural ligands interaction study, flavonoids and phenolic compounds bind in important amino acid residues of Asp 327, Asp 542, Arg 526, Asp 203, and His 600, which is similar with acarbose binding site [52]. In addition, Trp 59, Thr 163, His 305, Lys 200, Glu 233, and Tyr 151 are important amino acid residues of the binding site for alpha-amylase and acarbose complex [53]. Flavonoids and phenols of *G. procumbens* extracts show better binding affinity, and their interaction study represents a similar binding pattern. There have several scientific studies revealed the antidiabetic property of flavonoids and phenols. Our in silico study also strengthens the previous pharmacological findings on flavonoids and phenols of *G. procumbens*.

5. Conclusion

In this experimental study, *Gynura procumbens* leaf extract has shown its extensive use as an herbal treatment for type II diabetes. Our preclinical research in animal models imparted the efficiency of the ethanolic extracts of these leaves with extensive safety study evidence. A dose-dependent improvement of the health status of diseased rats indicated and encouraged the scientists to carry out a further clinical investigation to amplify the effect. An in silico study was conducted to examine an in-depth ligand-target interaction method where natural constituents of *G. procumbens* shared similar interaction sites like acarbose in both alpha-amylase and alpha-glucosidase enzymes. The phytocompounds of this plant gave better binding affinity than acarbose, thus reducing the postprandial hyperglycemia. Overall, it can be concluded that further investigation of *G. procumbens* at the molecular level can be conducted to bring a new dimension to the drug development process.

Data Availability

All data are included within the paper.

Ethical Approval

This study has been approved (Ref. no. 146/Biol. Scs.) by the Ethical Review Committee of the Faculty of Biological Sciences, University of Dhaka.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Authors’ Contributions

All the authors read the article meticulously and agreed to submit the original article.

Acknowledgments

This work was supported by a financial grant from the Grant for Advanced Research in Education (GARE) from Bangladesh Bureau of Educational Information and Statistics (BANBEIS) under the Ministry of Education, Government of the People’s Republic of Bangladesh, Project ID: LS 20191133 (no. 37.20.0000.004.033.020.2016.1053, dated: 13-10-2019).
References

[1] IDF. Type 2 diabetes, IDF, Brussels, Belgium, 2020, https://www.idf.org/aboutdiabetes/type-2-diabetes.html.

[2] Stanford University, Confronting South Asia’s Diabetes Epidemic, Stanford University, Stanford, CA, USA, 2020, https://fsi.stanford.edu/news/confronting-south-asia%E2%80%99s-diabetes-epidemic?fbclid=IwAR3wibUrb9Hygw-fld8sN2w4wlhbZ92cT35WzRkDcUxyCup-MiNf099v.

[3] R. Song, "Mechanism of metformin: a tale of two sites," *Diabetes Care*, vol. 39, no. 2, pp. 187–189, 2016.

[4] Diabetes.co.uk. Anti-Diabetic Drugs. Diabetes.co.uk. Coventry, UK, 2020, https://www.diabetes.co.uk/diabetes-medication/antidiabetic-drugs.html.

[5] D. D. Sears, G. Hsiao, A. Hsiao et al., "Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization," *Proceedings of the National Academy of Sciences*, vol. 106, no. 44, pp. 18745–18750, 2009.

[6] A. a. Nawawi, N. Nakamura, M. Hattori, M. Kurokawa, and K. Shiraki, "Inhibitory effects of Indonesian medicinal plants on the infection of herpes simplex virus type 1," *Phytotherapy Research*, vol. 13, no. 1, pp. 37–41, 1999.

[7] M. N. Iskander, Y. Song, I. M. Coupar, and W. Jiratchariyakul, "Antiinflammatory screening of the medicinal plant Gynura procumbens," *Plant Foods for Human Nutrition*, vol. 57, no. 3/4, pp. 233–244, 2002.

[8] K. W. Sok, M. Lee Sue Jann, S. Sudi et al., "Antimalarial and anti-inflammatory effects of Gynura procumbens are mediated by kaempferol via inhibition of glycogen synthase kinase 3β (GSK3β)," *Sains Malaysia*, vol. 44, no. 10, pp. 1489–1500, 2015.

[9] C. L. Keng, L. S. Yee, and P. L. Pin, "Micropropagation of Gynura procumbens (Lour.) Merr. an important medicinal plant," *Journal of Medicinal Plants Research*, vol. 3, no. 3, pp. 105–111, 2009.

[10] X. F. Zhang and B. K. Tan, "Effects of an ethanolic extract of Gynura procumbens on serum glucose, cholesterol and triglyceride levels in normal and streptozotocin-induced diabetic rats," *Singapore Medical Journal*, vol. 41, no. 1, pp. 9–13, 2000.

[11] G. A. Akowuah, A. Adikun, and A. Mariam, "Flavonoid identification and hypoglycaemic studies of the butanol fraction from Gynura procumbens," *Pharmaceutical Biology*, vol. 40, no. 6, pp. 405–410, 2002.

[12] M. Bohari, S. Pauliena, M. Hamid, K. Shariar, and N. Lajis, "Glucose uptake: stimulatory activity of Gynura procumbens in 3T3-F442A adipocytes, in Malaysian Medicinal Plant," *Chemistry and Biological Activity, UNIMAS and Malaysian Natural Products Society, Kota Samarahan, Malaysia*, 2006.

[13] M. Hamid, M. B. Saufi, F. R. I. M. Frim, and M. Nik Musaadah: Study on Antidiabetic Properties of Gynura procumbens Merr, 2020, https://agris.fao.org/agris-search/record?recordId=MY2010050118.

[14] Z. Hassan, M. F. Yam, M. Ahmad, and A. P. M. Yusof, "Antidiabetic properties and mechanism of action of Gynura procumbens water extract in streptozotocin-induced diabetic rats," *Molecules*, vol. 15, no. 12, pp. 9008–9023, 2010.

[15] S.-Z. Hoe, C.-N. Lee, S.-L. Mok, M. Y. Kamaruddin, and S.-K. Lam, "Gynura procumbens Merr decreases blood pressure in rats by vasodilatation via inhibition of calcium channels," *Clinics*, vol. 66, no. 1, pp. 143–150, 2011.

[16] S.-Z. Hoe, M. Y. Kamaruddin, and S.-K. Lam, "Inhibition of angiotensin-converting enzyme activity by a partially purified fraction of Gynura procumbens in spontaneously hypertensive rats," *Medical Principles and Practice*, vol. 16, no. 3, pp. 203–208, 2007.

[17] N. Balasuriya and H. P. V. Rupasinghe, "Antihypertensive properties of flavonoid-rich apple peel extract," *Food Chemistry*, vol. 135, no. 4, pp. 2320–2325, 2012.

[18] D. Lokesh and D. Amitsankar, "Evaluation of mechanism for antihypertensive action of Clerodendrum calebroxioumanum Walp., used by folklore healers in north-east India," *Journal of Ethnopharmacology*, vol. 143, no. 1, pp. 207–212, 2012.

[19] K. Algarizi, K. Y. Meng, J. J. Atangwo et al., "Hypoglycemic and anti-hyperglycemic study of Gynura procumbens leaf extracts," *Asian Pacific Journal of Tropical Biomedicine*, vol. 3, no. 5, pp. 358–366, 2013.

[20] N. Kaewscean, V. Suttikhum, and S. Siriamornpun, "Potential of Gynura procumbens leaves as source of flavonoid-enriched fractions with enhanced antioxidant capacity," *Journal of Functional Foods*, vol. 12, pp. 120–128, 2015.

[21] M. N. Sarian, Q. U. Ahmed, S. Z. Mat So’ad et al., "Antioxidant and anti-diabetic effects of flavonoids: a structure-activity relationship based study," *BioMed Research International*, vol. 2017, pp. 1–14, 2017.

[22] C. Sun, C. Zhao, E. C. Guven et al., "Dietary polyphenols as antidiabetic agents: advances and opportunities," *Food Frontiers*, vol. 1, no. 1, pp. 18–44, 2020, https://doi.org/10.1002/fff2.15.

[23] A. Unnikrishnan, S. S. Deepa, H. R. Herd, and A. Richardson, "Extension of life span in laboratory mice," in *Conn’s Handbook of Models for Human Aging*, J. L. Ram and P. M. Conn, Eds., pp. 245–270, Academic Press, 2nd edition, 2018.

[24] M. R. Tahsin, A. Sultana, M. S. Mohtasim Khan et al., "An evaluation of pharmacological healing potentialities of Terminalia Arjuna against several ailments on experimental rat models with an in-silico approach," *Heliyon*, vol. 7, no. 11, Article ID e08225, 2021.

[25] N. Brandstrup, J. E. Kirk, and C. Bruni, "The Hexokinase and Phosphoglucomoismerase Activities of Aortic and Pulmonary Artery Tissue in Individuals of Various Ages," *Journal of Gerontology*, vol. 12, no. 2, pp. 166–171, 1957.

[26] R. Malathi and M. Patrick Gomez, "Hepatoprotective Effect of Methanolic Leaves Extracts of Tylophora Asthmatica against Paracetamol-Induced Liver Damage in Rats," *Journal of Pharmacology and Toxicology*, vol. 2, pp. 737–742, https://scialert.net/fulltext/?doi=jpt.2007.737.742.

[27] J. E. Horrocks, J. Ward, and J. King, "A routine method for the determination of phosphoglucom isomerase activity in body fluid," *Journal of Clinical Pathology*, vol. 16, no. 3, pp. 248–251, 1963.

[28] J. M. Gancedo and C. Gancedo, "Fructose-1,6-diphosphatase, phosphofructokinase and glucose-6-phosphate dehydrogenase from fermenting and non fermenting yeasts," *Archiv fur Mikrobiologie*, vol. 76, no. 2, pp. 132–138, 1971.

[29] E. A. Abdel-Rahim, M. M. Rashid, Z. M. El-Hawai, M. M. Abdelkader, S. S. Kassem, and R. S. Mohamed, "Anti-diabetic effect of cichorium intybus leaves and plantago ovate seeds in high fat-diet-streptozotocin induced diabetic rats," *J. Food Nutr. Res.*, vol. 4, no. 5, 2016.

[30] V. Saks, N. Beraud, and T. Wallimann, "Metabolic compartmentation - a system level property of muscle cells," *International Journal of Molecular Sciences*, vol. 9, no. 5, pp. 751–767, 2008.

[31] L. J. Lemasters, C. R. Hackenbrock, R. G. Thurman, and
H. V. Westerhoff, Eds., Springer, Boston, MA, USA, pp. 617–622, 1988.

[32] G. M. Lawrence, M. A. Jepson, I. P. Trayer, and D. G. Walker, “The compartmentation of glycolytic and gluconeogenic enzymes in rat kidney and liver and its significance to renal and hepatic metabolism,” The Histochemical Journal, vol. 18, no. 1, pp. 45–53, 1986.

[33] H. B. Burch, R. G. Narins, C. Chu et al., “Distribution along the rat nephron of three enzymes of gluconeogenesis in acidois and starvation,” American Journal of Physiology - Renal Physiology, vol. 235, no. 3, pp. F246–F253, 1978.

[34] D. Sasse, H. F. Teutsch, N. Katz, and K. Jungermann, “The development of functional heterogeneity in the liver parenchyma of the golden hamster,” Anatomy and Embryology, vol. 156, no. 2, pp. 153–163, 1979.

[35] N. Katz, H. F. Teutsch, K. Jungermann, and D. Sasse, “Heterogeneous reciprocal localization of fructose-1,6-bis-phosphatase and of glucokinase in microdissected perportal and perivenous rat liver tissue,” FEBS Letters, vol. 83, no. 2, pp. 272–276, 1977.

[36] U. Schmidt, H. Schmid, W. G. Guder, B. Funk, A. Mall, and J. Weis, “Liver cell heterogeneity,” Biological Chemistry, vol. 359, no. 1, pp. 193–198, 1978.

[37] U. Schmidt, I. Marovsari, and U. C. Dubach, “Renal metabolism of glucose: anatomical sites of hexokinase activity in the rat nephron,” FEBS Letters, vol. 53, no. 1, pp. 26–28, 1975.

[38] H. Schmid, A. Mall, M. Scholz, and U. Schmidt, “Unchanged glycolytic capacity in rat kidney under conditions of stimulated gluconeogenesis. Determination of phosphofructokinase and pyruvate kinase in microdissected nephron segments of fasted and acidic animals,” Hoppe-Seyler’s Zeitschrift für physiologische Chemie, vol. 361, no. 1, pp. 819–828, 1980.

[39] A. Vandewalle, G. Wirthschnoeh, H. G. Heidrich, and W. G. Guder, “Distribution of hexokinase and phosphoenolpyruvate carboxykinase along the rabbit nephron,” American Journal of Physiology - Renal Physiology, vol. 240, no. 6, pp. F492–F500, 1981.

[40] W. G. Guder and U. Schmidt, “Liver cell heterogeneity. The distribution of pyruvate kinase and phosphoenolpyruvate carboxykinase (GTP) in the liver lobule of fed and starved rats,” Hoppe-Seyler’s Zeitschrift für physiologische Chemie, vol. 357, no. 2, pp. 1793–1800, 1976.

[41] M. Trus, K. Zawalich, D. Gaynor, and F. Matschinsky, “Hexokinase and glucokinase distribution in the liver lobule,” Journal of Histochemistry and Cytochemistry, vol. 28, no. 6, pp. 579–581, 1980.

[42] H. F. Teutsch, “Chemomorphology of liver parenchyma. Qualitative histochemical distribution patterns and quantitative sinusoidal profiles of G6Pase, G6PDH and malic enzyme activity and of glycogen content,” Progress in Histochemistry and Cytochemistry, vol. 14, no. 3, pp. 1–92, 1981.

[43] W. Fischer, M. Ick, and N. R. Katz, “Reciprocal distribution of hexokinase and glucokinase in the perportal and perivenous zone of the rat liver acinus,” Hoppe-Seyler’s Zeitschrift für physiologische Chemie, vol. 363, no. 1, pp. 375–380, 1982.

[44] B. Ragavan and S. Krishnakumari, “Antidiabetic effect of T. arjuna bark extract in alloxan induced diabetic rats,” Indian Journal of Clinical Biochemistry, vol. 21, no. 2, pp. 123–128, 2006.

[45] C. Ewenighi, U. Dimkpa, J. Onyeanusi, L. Onoh, G. Onoh, and U. Ezeugwu, “Estimation of glucose level and body weight in alloxan induced diabetic rat treated with aqueous extract of Garcinia kola seed,” The Ulutas Medical Journal, vol. 1, no. 2, p. 26, 2015.

[46] K. Algariri, I. J. Atangwho, K. Y. Meng, M. Z. Asmawi, A. Sadikun, and V. Murugaiyah, “Antihyperglycaemic and toxicological evaluations of extract and fractions of Gynura procumbens leaves,” Tropical Life Sciences Research, vol. 25, no. 1, pp. 75–93, 2014.

[47] B. Sharma, M. S. Siddiqui, and G. Ram, “Rejuvenating of Kidney Tissues on Alloxan Induced Diabetic Mice under the Effect of Momordica Charantia,” Advances in Pharmaceutics, vol. 2014, 2014, https://www.hindawi.com/journals/ap/2014/439158/.

[48] V. E. Okpashi, L. I. Ofoelo, and N. Ofc, “Assessment of lipid profile indices of alloxan-induced diabetic rats using irvingia gabononesis seeds extracts,” Translational Biomedicine, vol. 8, no. 4, 2017.

[49] K. A. Ahmad Nazri, “Gynura procumbens standardised extract reduces cholesterol levels and modulates oxidative status in postmenopausal rats fed with cholesterol diet enriched with repeatedly heated palm oil’, evid. Based complement,” Alternative Medicine, vol. 2019, Article ID e7246756, 2019.

[50] N. Kaewseejan, V. Sutthiskhum, and S. Siriamornpun, “Potential of Gynura procumbens leaves as source of flavonoid-enriched fractions with enhanced antioxidant capacity,” Journal of Functional Foods, vol. 12, pp. 120–128, 2015.

[51] Z. Islam, “In vivo assessment of antidiabetic potential and mapping of pharmacological properties of ethanolic extract of leaves of coccinia grandis on alloxan-induced diabetic rats,” Asian Journal of Advanced Research and Reports, vol. 7, no. 2, pp. 1–9, 2019.

[52] I. Sim, K. Jayakanthan, S. Mohan, R. Nasi, and B. D. Johnston, “New glucosidase inhibitors from an ayurvedic herbal treatment for type 2 diabetes: structures and inhibition of human intestinal maltase-glucoamylase with compounds from Salacia reticulata,” Biochemistry, vol. 49, no. 3, pp. 443–451, 2010.

[53] C.-H. Jhong, J. Riyaphan, S.-H. Lin, Y.-C. Chia, and C.-F. Weng, “Screening alpha-glucosidase and alpha-amylase inhibitors from natural compounds by molecular docking in silico,” BioFactors Oxf. Engl., vol. 41, no. 4, pp. 242–251, 2015.